Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET)

Macrovascular disease is the major cause of mortality in persons with type 2 diabetes mellitus, and hypertension is an important factor contributing to this high prevalence. High blood pressure is about twice as common in persons with diabetes mellitus as in those without. Up to 75% of diabetes-related cardiovascular complications are attributed to hypertension. These observations are part of the rationale for recommendations for more aggressive lowering of blood pressure (to < 130/85 mm Hg) in persons with coexistent diabetes and hypertension. This may require therapy with a combination of antihypertensive agents. The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET), discussed herein, supports the case for combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist in diabetic patients with hypertension.

[1]  Veikko Salomaa,et al.  Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. , 1995, Circulation.

[2]  J. Sowers.  Impact of lipid and ACE inhibitor therapy on cardiovascular disease and metabolic abnormalities in the diabetic and hypertensive patient , 1997, Journal of Human Hypertension.

[3]  J. Sowers,et al.  Metabolic abnormalities in cardiac ischemia. , 1995, Cardiology clinics.

[4]  Donald E McMillan,et al.  Development of Vascular Complications in Diabetes , 1997, Vascular medicine.

[5]  D. Giugliano,et al.  Protein C Deficiency in Insulin-Dependent Diabetes: A Hyperglycemia-Related Phenomenon , 1990, Thrombosis and Haemostasis.

[6]  R. Califf,et al.  Hypertension and Diabetes and the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET): More ammunition against surrogate end points , 1998, Diabetes Care.

[7]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[8]  W. Weintraub,et al.  Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. , 1995, Circulation.

[9]  J. Sowers,et al.  Diabetes mellitus: A disease of abnormal cellular calcium metabolism? , 1994 .

[10]  J E Tooke,et al.  Microvascular Function in Human Diabetes: A Physiological Perspective , 1995, Diabetes.

[11]  G. Bakris,et al.  Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. , 1996, Archives of internal medicine.

[12]  J. Sowers,et al.  Plasma Antithrombin III and Thrombin Generation Time: Correlation with Hemoglobin A1 and Fasting Serum Glucose in Young Diabetic Women , 1980, Diabetes Care.

[13]  S. Ellenberg.  Surrogate end points in clinical trials. , 1991, BMJ.

[14]  G. Bakris,et al.  Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  J. Sowers,et al.  Treatment of Elderly Hypertensive Patients With Diabetes, Renal Disease, and Coronary Heart Disease. , 1996, The American journal of geriatric cardiology.

[16]  J. Moyer,et al.  Newer approaches to antihypertensive therapy. , 1960, Journal of the American Medical Association.

[17]  G. Bakris,et al.  Therapeutic challenges in the obese diabetic patient with hypertension. , 1996, The American journal of medicine.

[18]  R. Natarajan,et al.  Intracellular Free Magnesium Deficiency Plays a Key Role in Increased Platelet Reactivity in Type II Diabetes Mellitus , 1992, Diabetes Care.

[19]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[20]  J. Sowers,et al.  Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. , 1994, The Journal of laboratory and clinical medicine.

[21]  John E. Tooke,et al.  Perspectives in Diabetes Microvascular Function in Human Diabetes , 1995 .

[22]  Y. Ozaki,et al.  Phosphorylation of Myosin Light Chain in Resting Platelets From NIDDM Patients Is Enhanced: Correlation With Spontaneous Aggregation , 1997, Diabetes.

[23]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[24]  J. Sowers,et al.  Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. , 1995, Hypertension.

[25]  P. Taylor,et al.  Glaxo/MRS Young Investigator Prize. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. , 1995, Clinical science.

[26]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[27]  J. Sowers,et al.  Diabetes mellitus and cardiovascular disease in women. , 1998, Archives of internal medicine.

[28]  R. Rosenson,et al.  Lipoprotein Lp(a) excess and coronary heart disease. , 1997, Archives of internal medicine.

[29]  A. Kanagasabapathy,et al.  Rate of Progression of Albuminuria in Type II Diabetes: Five-year prospective study from South India , 1994, Diabetes Care.

[30]  J. Sowers,et al.  Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension. , 1993, American Journal of Hypertension.

[31]  C. Cronin,et al.  Microalbuminuria in patients with non-insulin-dependent diabetes mellitus relates to nocturnal systolic blood pressure. , 1997, The American journal of medicine.

[32]  J. Sowers,et al.  Metabolic abnormalities in hypertension , 1997, Current opinion in nephrology and hypertension.

[33]  N. Doba,et al.  The relationship of hyperinsulinemic state to left ventricular hypertrophy, microalbuminuria, and physical fitness in borderline and mild hypertension. , 1997, American journal of hypertension.

[34]  R. Elton,et al.  Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. , 1992, Atherosclerosis.

[35]  J. Sowers,et al.  Obesity and cardiovascular disease. , 1998, Clinical chemistry.

[36]  L. Poston,et al.  Oxidative Stress and Lipids in Diabetes: A Role in Endothelium Vasodilator Dysfunction? , 1996, Vascular Medicine.

[37]  Lippincott Williams Wilkins,et al.  National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes , 1994, Hypertension.